Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EUJune 11, 2017
Clarification on the news article by Commercial TimesJune 29, 2017
- Date of the meeting: June 28, 2017
- Resolution #1: The 2016 earning distribution and expense appropriation was recognized.
- Resolution #2: Amended items—None
- Resolution #3: The 2016 Annual report and financial report was recognized.
- Resolution #4: Election of Board Directors and Supervisors—None
- Resolution #5: Others—Passed the amendment of “Procedure of asset acquisition and disposal.”
- Any other matters that need to be specified: None.